USPTO issues patent on Neurolixis Parkinson's disease drug candidate
WILMINGTON, Del. - Feb. 4, 2020 - PRLog -- The United States Patent and Trademark Office (USPTO) has issued a patent on NLX-112, a drug candidate developed by Neurolixis for treatment of human movement disorders, notably levodopa-induced dyskinesia in Parkinson's disease. The invention is based on a clinical trial in which sustained release formulations of NLX-112 were tested in healthy volunteers. The sustained release formulations stabilized plasma levels of NLX-112 and avoided side effects of dizziness and nausea.
The patent (US 10,548,885 B2), which protects the use of NLX-112 in the US until 2035, has already issued in the European Union, Canada, Australia and Russia, and is pending in other territories.
Adrian Newman-Tancredi, PhD, DSc, of Neurolixis commented, "We are delighted that the patent has been issued. Movement disorders are a major healthcare challenge, particularly among aging populations in many developed nations, and this US patent strengthens the commercial prospects of NLX-112 in this major pharmaceutical market."
NLX-112 (also known as befiradol) acts on the brain's serotonin system and is a particularly specific and efficacious activator of neuronal proteins known as 5-HT1A receptors. By targeting these receptors, NLX-112 potently and efficaciously reduces dyskinesias in rodent and non-human primate models of Parkinson's disease. NLX-112 is orally administered and has been safely tested in over 500 human subjects. Neurolixis plans to investigate the antidyskinetic activity of NLX-112 in patients with L-DOPA-induced Parkinson's disease and, potentially, with other movement disorders.
About Neurolixis, Inc.
Neurolixis, with offices in the USA and France, is a privately held biotechnology company developing therapies for disorders of the central nervous system. The Company has two clinical programs: NLX‑112 is a Phase 2-ready program targeting Levodopa-induced dyskinesia in Parkinson's disease, and NLX-101 is a Phase 1 drug candidate targeting Rett syndrome. Additional discovery programs target psychiatric disorders such as depression.
Forward Looking Statement
This press release includes forward-looking statements that represent our judgment as of the date of the release. They involve uncertainties, including dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing new technologies, as well as other risks. Actual results may differ materially from those projected. Neurolixis disclaims any intent or obligation to update these forward-looking statements.
Dr Adrian Newman-Tancredi,
CEO, Neurolixis Inc.
Page Updated Last on: Feb 05, 2020